Rifaximin Improves Systemic Hemodynamics and Renal Function in Patients With Alcohol-Related Cirrhosis and Ascites

Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement

Albillos, A., de la Hera, A., González, M., Moya, J. L., Calleja, J. L., Monserrat, J., Ruíz-del-Árbol, L., & Álvarez‐Mon, M. (2003) · Hepatology · doi:10.1053/jhep.2003.50038 · Cited by 445 · see citing works

Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: Relationship with the development of renal impairment and mortality

Navasa, M., Follo, A., Filella, X., Jiménez, W., Francitorra, A., Planas, R., Rimola, A., Arroyo, V., & Rodés, J. (1998) · Hepatology · doi:10.1002/hep.510270507 · Cited by 429 · see citing works

Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophaegeal varices, and hyperdynamic circulation.

Lin, R.-S., Lee, F.-Y., Lee, S.-D., Tsai, Y.-T., Lin, H. C., Rei-Hwa, L., Wan-Ching, H., Cheng-Chun, H., Sun-Sang, W., & Kwang-Juei, L. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80424-2 · Cited by 355 · see citing works

Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility

Wiest, R., Das, S., Cadelina, G. W., García–Tsao, G., Milstien, S., & Groszmann, R. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7458 · Cited by 305 · see citing works

The Effect of Selective Intestinal Decontamination on the Hyperdynamic Circulatory State in Cirrhosis

Rasaratnam, B., Kaye, D. M., Jennings, G., Dudley, F. J., & Chin-Dusting, J. P. F. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-3-200308050-00008 · Cited by 215 · see citing works

Gut microflora in the pathogenesis of the complications of cirrhosis

García–Tsao, G., & Wiest, R. (2004) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2003.10.005 · Cited by 190 · see citing works

Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases

Koo, H. L., & DuPont, H. L. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328333dc8d · Cited by 189 · see citing works

Intestinal decontamination improves liver haemodynamics in patients with alcohol‐related decompensated cirrhosis

VLACHOGIANNAKOS, J., SAVERIADIS, A. S., VIAZIS, N., THEODOROPOULOS, I., FOUDOULIS, K., MANOLAKOPOULOS, S., RAPTIS, S., & KARAMANOLIS, D. G. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.03958.x · Cited by 163 · see citing works

The hyperdynamic circulation in cirrhosis

Blendis, L. M., & Wong, F. S.-H. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00124-3 · Cited by 154 · see citing works

Thalidomide Inhibits Tumor Necrosis Factor α, Decreases Nitric Oxide Synthesis, and Ameliorates the Hyperdynamic Circulatory Syndrome in Portal–Hypertensive Rats

López-Talavera, J. C., Cadelina, G. W., Olchowski, J., Merrill, W., & Groszmann, R. J. (1996) · Hepatology · doi:10.1002/hep.510230644 · Cited by 138 · see citing works

Plasma Interleukin-6 Levels in Patients with Cirrhosis Relationship to Endotoxemia, Tumor Necrosis Factor-α, and Hyperdynamic Circulation

LEE, F., Lu, R. H., Tsai, Y. T., Lin, H., Hou, M., Li, C. P., Liao, T.-M., LIN, L., Wang, S.-S., & Lee, S. D. (1996) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529609006772 · Cited by 102 · see citing works

Tumor necrosis factor-α induces renal vasoconstriction as well as natriuresis in mice

Shahid, M., Francis, J., & Majid, D. S. A. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90297.2008 · Cited by 94 · see citing works

Functional renal failure and haemorrhagic gastritis associated with endotoxaemia in cirrhosis.

Clemente, C. M., Bosch, J., Rodés, J., Arroyo, V., Mas, A., & Maragall, S. (1977) · Gut · doi:10.1136/gut.18.7.556 · Cited by 90 · see citing works

Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis

Runyon, B. A., Borzio, M., Young, S., Squier, S. U., Guarner, C., & Runyon, M. A. (1995) · Hepatology · doi:10.1002/hep.1840210634 · Cited by 77 · see citing works

Increased tumour necrosis factor   production in mesenteric lymph nodes of cirrhotic patients with ascites

Genesca, J. (2003) · Gut · doi:10.1136/gut.52.7.1054 · Cited by 70 · see citing works

Effect of Fluoroquinolone on the Enhanced Nitric Oxide-Induced Peripheral Vasodilation Seen in Cirrhosis

Chin-Dusting, J. P. F., Rasaratnam, B., Jennings, G. L. R., & Dudley, F. J. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-11-199712010-00007 · Cited by 68 · see citing works

Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats

Lopez-Talavera, J. (1996) · Hepatology · doi:10.1053/jhep.1996.v23.pm0008675185 · Cited by 63 · see citing works

Endotoxin clearance and its relation to hepatic and renal disturbances in rats with liver cirrhosis

Nakatani, Y., Fukui, H., Kitano, H., Nagamoto, I., Tsujimoto, T., Kuriyama, S., Kikuchi, E., Hoppou, K., & Tsujii, T. (2001) · Liver International · doi:10.1034/j.1600-0676.2001.210110.x · Cited by 36 · see citing works

Effect of Paromomycin Sulfate on Endotoxemia in Patients with Cirrhosis

Tarao, K., Moroi, T., Hirabayashi, Y., Ikeuchi, T., Endo, O., & Takamura, Y. (1982) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-198206000-00013 · Cited by 13 · see citing works

Subacute endotoxemia in dogs with experimental cirrhosis and ascites: effects on kidney function

Levy, M., & Wexler, M. J. (1984) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y84-110 · Cited by 12 · see citing works

Liver cirrhosis

Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60121-5 · Cited by 1,823 · see citing works

Alcohol, liver disease and the gut microbiota

Bajaj, J. S. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0099-1 · Cited by 706 · see citing works

The gut microbiome and liver cancer: mechanisms and clinical translation

Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634 · see citing works

Abdominal contributions to cardiorenal dysfunction in congestive heart failure.

Verbrugge, F. H., Dupont, M., Steels, P., Grieten, L., Malbrain, M., Tang, W. H. W., & Mullens, W. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.070 · Cited by 380 · see citing works

Cirrhosis, bile acids and gut microbiota: Unraveling a complex relationship

Ridlon, J. M., Alves, J. M., Hylemon, P. B., & Bajaj, J. S. (2013) · Gut Microbes · doi:10.4161/gmic.25723 · Cited by 336 · see citing works

Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis

Nagatomo, Y., & Tang, W. H. W. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.09.017 · Cited by 259 · see citing works

The gut microbiota: A treasure for human health

Li, D., Wang, P., Wang, P., Hu, X., & Chen, F. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.08.003 · Cited by 265 · see citing works

Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications

Bellot, P., Francés, R., & Such, J. M. (2012) · Liver International · doi:10.1111/liv.12021 · Cited by 255 · see citing works

Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy

Iwakiri, Y., & Trebicka, J. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100316 · Cited by 237 · see citing works

Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy

Kimer, N., Krag, A., Møller, S., Bendtsen, F., & Gluud, L. L. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12803 · Cited by 203 · see citing works

Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure

Trebicka, J., Bork, P., Krag, A. A., & Arumugam, M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00376-3 · Cited by 203 · see citing works

Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia

Fukui, H. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i3.425 · Cited by 195 · see citing works

The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt

Bureau, C., Thabut, D., Jézequel, C., Archambeaud, I., d’Altéroche, L., Dharancy, S., Borentain, P., Oberti, F., Plessier, A., de Lédinghen, V., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-0202 · Cited by 186 · see citing works

Gut dysbiosis associated with hepatitis C virus infection

Inoue, T., Nakayama, J., Moriya, K., Kawaratani, H., Momoda, R., Ito, K., Iio, E., Nojiri, S., Fujiwara, K., Yoneda, M., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy205 · Cited by 183 · see citing works

Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation

Nicoletti, A., Ponziani, F. R., Biolato, M., Valenza, V., Marrone, G., Sganga, G., Gasbarrini, A., Miele, L., & Grieco, A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i33.4814 · Cited by 170 · see citing works

Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial

Pose, E., Napoleone, L., Amin, A., Campion, D., Jimenez, C., Piano, S., Roux, O., Uschner, F. E., de Wit, K., Zaccherini, G., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30320-6 · Cited by 154 · see citing works

The Use of Rifaximin in Patients With Cirrhosis

Caraceni, P., Vargas, V., Solà, E., Alessandria, C., de Wit, K., Trebicka, J., Angeli, P., Mookerjee, R. P., Durand, F., Pose, E., et al. (2021) · Hepatology · doi:10.1002/hep.31708 · Cited by 142 · see citing works

Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications

Ponziani, F. R., Zocco, M. A., Cerrito, L., Gasbarrini, A., & Pompili, M. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1481747 · Cited by 139 · see citing works

Long-term Use of Antibiotics and Proton Pump Inhibitors Predict Development of Infections in Patients With Cirrhosis

O’Leary, J. G., Reddy, K. R., Wong, F. S.-H., Kamath, P. S., Patton, H. M., Biggins, S. W., Fallon, M. B., García–Tsao, G., Subramanian, R., Malik, R., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.060 · Cited by 132 · see citing works

Critical Roles of Kupffer Cells in the Pathogenesis of Alcoholic Liver Disease: From Basic Science to Clinical Trials

Zeng, T., Zhang, C., Xiao, M., Yang, R., & Xie, K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00538 · Cited by 130 · see citing works

Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis

Bajaj, J. S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13435 · Cited by 122 · see citing works

Review article: alcohol and gut microbiota ‐ the possible role of gut microbiota modulation in the treatment of alcoholic liver disease

Vassallo, G. A., Mirijello, A., Ferrulli, A., Antonelli, M., Landolfi, R., Gasbarrini, A., & Addolorato, G. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13164 · Cited by 121 · see citing works

Gut Microbiota-Kidney Cross-Talk in Acute Kidney Injury

Gong, J., Noel, S., Pluznick, J. L., Hamad, A. R. A., & Rabb, H. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.10.009 · Cited by 118 · see citing works

Rifaximin: beyond the traditional antibiotic activity

Calanni, F., Renzulli, C., Barbanti, M., & Viscomi, G. C. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.106 · Cited by 119 · see citing works

Targeting the gut barrier for the treatment of alcoholic liver disease

Zhou, Z., & Zhong, W. (2017) · Liver Research · doi:10.1016/j.livres.2017.12.004 · Cited by 113 · see citing works

Gut-liver axis signaling in portal hypertension

Simbrunner, B., Mandorfer, M., Trauner, M., & Reiberger, T. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i39.5897 · Cited by 113 · see citing works

Antibiotics for the treatment of hepatic encephalopathy

Patidar, K. R., & Bajaj, J. S. (2013) · Metabolic Brain Disease · doi:10.1007/s11011-013-9383-5 · Cited by 110 · see citing works

Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis

Bajaj, J. S., Ratliff, S. M., Heuman, D. M., & Lapane, K. L. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12045 · Cited by 108 · see citing works

Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy

Kang, S. H., Lee, Y. B., Lee, J., Nam, J. Y., Chang, Y. W., Cho, H., Yoo, J., Cho, Y. Y., Cho, E. J., Yu, S. J., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14275 · Cited by 100 · see citing works

Beyond scoring: a modern interpretation of disease progression in chronic liver disease

Rosselli, M., MacNaughtan, J., Jalan, R., & Pinzani, M. (2013) · Gut · doi:10.1136/gutjnl-2012-302826 · Cited by 96 · see citing works

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach

Soldi, S., Vasileiadis, S., Uggeri, F., Campanale, M. C., Morelli, L., Calanni, F., Grimaldi, M., Gasbarrini, A., & Fogli, M. V. (2015) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s89999 · Cited by 96 · see citing works

Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications

Tsiaoussis, G. I. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i17.2058 · Cited by 82 · see citing works

Novel perspectives in the management of decompensated cirrhosis

Bernardi, M., & Caraceni, P. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0045-2 · Cited by 79 · see citing works

Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea

Pimentel, M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13437 · Cited by 76 · see citing works

Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double‐blind, placebo‐controlled trial

Kimer, N., Pedersen, J. S., Busk, T. M., Gluud, L. L., Hobolth, L., Krag, A. A., Møller, S., Bendtsen, F., & Copenhagen Rifaximin (CoRif) Study Group (2016) · Hepatology · doi:10.1002/hep.28898 · Cited by 75 · see citing works

Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial

Kimer, N., Pedersen, J. S., Tavenier, J., Christensen, J. E., Busk, T. M., Hobolth, L., Krag, A. A., Al‐Soud, W. A., Mortensen, M. S., Sørensen, S. J., et al. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13852 · Cited by 66 · see citing works

Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis

Dong, T. S., Aronsohn, A. I., Reddy, K. G., & Te, H. S. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4313-0 · Cited by 63 · see citing works

Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management

Algora, S. B. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i42.12125 · Cited by 61 · see citing works

Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association

Cresci, S., Pereira, N. L., Ahmad, F., Byku, M., Fuentes, L. D. L., Lanfear, D. E., Reilly, C. M., OWENS, A. T., & Wolf, M. J. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000058 · Cited by 60 · see citing works

Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis

Luo, M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i41.11815 · Cited by 56 · see citing works

Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure

Trebicka, J., Reiberger, T., & Laleman, W. (2018) · Visceral Medicine · doi:10.1159/000490262 · Cited by 56 · see citing works

Markers of bacterial translocation in end-stage liver disease

Koutsounas, I. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i20.2264 · Cited by 55 · see citing works

Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step

Fukui, H. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00008 · Cited by 52 · see citing works

Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study

Lv, X.-Y., Ding, H.-G., Zheng, J.-F., Fan, C., & Li, L. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i2.199 · Cited by 51 · see citing works

Simvastatin and Rifaximin in Decompensated Cirrhosis

Pose, E., Jiménez, C., Zaccherini, G., Campion, D., Piano, S. S., Uschner, F. E., de Wit, K., Roux, O., Gananandan, K., Laleman, W., et al. (2025) · JAMA · doi:10.1001/jama.2024.27441 · Cited by 49 · see citing works

Intestinal permeability in a patient with liver cirrhosis

Aguirre-Valádez, J., Rivera-Espinosa, L., Méndez-Guerrero, O., Chávez-Pacheco, J. L., Juárez, I. G., & Torre, A. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s115902 · Cited by 50 · see citing works

Current and future pharmacological therapies for managing cirrhosis and its complications

Koeckerling, D., Nathwani, R., Forlano, R., Manousou, P., Mullish, B. H., & Dhar, A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i8.888 · Cited by 49 · see citing works

Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection

El‐Mowafy, M., Elgaml, A., El‐Mesery, M., Sultan, S., Ahmed, T. A., Gomaa, A. I., Aly, M., & Mottawea, W. (2021) · Biology · doi:10.3390/biology10010055 · Cited by 47 · see citing works

Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis

Zacharias, H. D., Kamel, F., Tan, J. Y., Kimer, N., Gluud, L. L., & Morgan, M. Y. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011585.pub2 · Cited by 49 · see citing works

Pathophysiology of Hepatorenal Syndrome – Acute Kidney Injury

Adebayo, D., & Wong, F. S.-H. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.034 · Cited by 48 · see citing works

The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer

M�ndez-S�nchez, N., Valencia-Rodríguez, A., Vera-Barajas, A., Abenavoli, L., Scarpellini, E., & Rodríguez, G. P. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2019.29 · Cited by 43 · see citing works

Gut microbiota-modulating agents in alcoholic liver disease: Links between host metabolism and gut microbiota

Jung, J. H., Kim, S. E., Suk, K. T., & Kim, D. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.913842 · Cited by 42 · see citing works

Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis

Han, J. W., Kim, D. I., Nam, H. C., Chang, U. I., Yang, J. M., & Song, D. S. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0082 · Cited by 41 · see citing works

Hepatic encephalopathy in acute-on-chronic liver failure

Lee, G. H. (2015) · Hepatology International · doi:10.1007/s12072-015-9626-0 · Cited by 41 · see citing works

Roles of Gut Microbiota in Alcoholic Liver Disease

Zhang, D., Liu, Z., & Bai, F. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s420195 · Cited by 39 · see citing works

Management of refractory cirrhotic ascites: challenges and solutions

Fukui, H., Kawaratani, H., Kaji, K., Takaya, H., & Yoshiji, H. (2018) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s136578 · Cited by 39 · see citing works

Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers

Madsen, B. S., Havelund, T., & Krag, A. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0044-1 · Cited by 38 · see citing works

Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis

Macnaughtan, J., & Jalan, R. (2015) · The American Journal of Gastroenterology · doi:10.1038/ajg.2015.313 · Cited by 38 · see citing works

Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002–2018: A Systematic Review and Meta-Analysis

Thomson, M. J., Taylor, A., Sharma, P., Lok, A. S.-F., & Tapper, E. B. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05858-2 · Cited by 38 · see citing works

Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy

Mangas‐Losada, A., García‐García, R., Leone, P., Ballester, M. P., Cabrera‐Pastor, A., Urios, A., Gallego, J., Martínez-Pretel, J.-J., Giménez‐Garzó, C., Revert, F., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2046-5 · Cited by 34 · see citing works

The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients

Mostafa, T. M., Badra, G., & Abdallah, M. (2015) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2015.7782 · Cited by 34 · see citing works

New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases

Bajaj, J. S., Barbara, G., DuPont, H. L., Mearin, F., Gasbarrini, A., & Tack, J. F. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.04.020 · Cited by 32 · see citing works

Novel treatment options for portal hypertension

Schwabl, P., & Laleman, W. (2017) · Gastroenterology report · doi:10.1093/gastro/gox011 · Cited by 31 · see citing works

The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial

Kimer, N., Meldgaard, M., Hamberg, O., Kronborg, T. M., Lund, A. M., Møller, H. J., Bendtsen, F., & Ytting, H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264278 · Cited by 30 · see citing works

The heart and gut relationship: a systematic review of the evaluation of the microbiome and trimethylamine-N-oxide (TMAO) in heart failure

Anderson, K. M., Ferranti, E. P., Alagha, E. C., Mykityshyn, E., French, C., & Reilly, C. M. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10254-6 · Cited by 29 · see citing works

The Microbiome–Gut–Brain Axis, a Potential Therapeutic Target for Substance-Related Disorders

Fu, X., Chen, T., Cai, J., Liu, B., Zeng, Y., & Zhang, X. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.738401 · Cited by 28 · see citing works

Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival

Hanafy, A. S., & Hassaneen, A. M. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000743 · Cited by 28 · see citing works

The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease

Lopetuso, L. R., Napoli, M., Rizzatti, G., & Gasbarrini, A. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1483333 · Cited by 27 · see citing works

Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease

Hyun, J. Y., Kim, S. K., Yoon, S. J., Lee, S. B., Jeong, J., Gupta, H., Sharma, S. P., Oh, K., Won, S., Kwon, G.-H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158749 · Cited by 25 · see citing works

Future treatments of cirrhosis

Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.902303 · Cited by 24 · see citing works

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis

Pose, E., Solà, E., Lozano, J. J., Juanola, A., Sidorova, J., Zaccherini, G., de Wit, K., Uschner, F. E., Tonon, M., Kazankov, K., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1881 · Cited by 27 · see citing works

Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome

Ibrahim, E.-S., Alsebaey, A., Zaghla, H., Abdelmageed, S. M., Gamel, K. A. E. M., & Abdelsameea, E. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000967 · Cited by 22 · see citing works

Renal dysfunction in patients with cirrhosis: Where do we stand?

Pipili, C. (2014) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v5.i3.156 · Cited by 22 · see citing works

Advanced Bioinspired Multifunctional Platforms Focusing on Gut Microbiota Regulation

Li, M., Wang, L., Lin, D., Liu, Z., Wang, H., Yang, Y., Sun, C., Ye, J., & Liu, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c05013 · Cited by 22 · see citing works

The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status

Stojić, J., Kukla, M., & Grgurević, I. (2023) · Diagnostics · doi:10.3390/diagnostics13182960 · Cited by 21 · see citing works

Future therapy of portal hypertension in liver cirrhosis – a guess

Sauerbruch, T., & Trebicka, J. (2014) · F1000Prime Reports · doi:10.12703/p6-95 · Cited by 21 · see citing works

Potential therapies for acute‐on‐chronic liver failure

Morrison, M. A., Artru, F., Trovato, F. M., Triantafyllou, E., & McPhail, M. J. W. (2023) · Liver International · doi:10.1111/liv.15545 · Cited by 22 · see citing works

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin

Chang, C. H. (2018) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s167031 · Cited by 16 · see citing works

Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease

Ranjbarian, T., & Schnabl, B. (2023) · Seminars in Liver Disease · doi:10.1055/a-2145-7331 · Cited by 16 · see citing works

Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis

Mendoza, Y. P., Rodrigues, S. G., Bosch, J., & Berzigotti, A. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.06.048 · Cited by 16 · see citing works

Liver cirrhosis and complications from the perspective of dysbiosis

Nie, G., Zhang, H., Xie, D., Yan, J., & Li, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1320015 · Cited by 15 · see citing works

Therapeutic potential of rifaximin in liver diseases

Yang, W., Guo, G., & Sun, C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117283 · Cited by 14 · see citing works

Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy

Coronel-Castillo, C. E., Contreras-Carmona, J., Frati-Munari, A. C., Uribe, M., & Méndez‐Sánchez, N. (2020) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2019.09.003 · Cited by 12 · see citing works

Hepatorenal syndrome: pathophysiology and evidence-based management update

Hasan, I., Rashid, T., Chirilă, R. M., Ghali, P., & Wadei, H. M. (2021) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2021-0006 · Cited by 12 · see citing works

The contributions of bacteria metabolites to the development of hepatic encephalopathy

Gilbert, M. C., Setayesh, T., & Wan, Y. Y. (2022) · Liver Research · doi:10.1016/j.livres.2022.11.005 · Cited by 11 · see citing works

From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension

Porada, M., & Bułdak, Ł. (2025) · Metabolites · doi:10.3390/metabo15020072 · Cited by 10 · see citing works

Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites

Yokoyama, K., Fukuda, H., Yamauchi, R., Higashi, M., Miyayama, T., Higashi, T., Uchida, Y., Shibata, K., Tsuchiya, N., Fukunaga, A., et al. (2022) · Medicina · doi:10.3390/medicina58091276 · Cited by 10 · see citing works

The Impact of Renal Function on Hepatic Encephalopathy Following TIPS Placement for Refractory Ascites

Zhao, M. Y., Saab, S., Craw, C., & Lee, E. W. (2023) · Biomedicines · doi:10.3390/biomedicines11082171 · Cited by 9 · see citing works

Papel de la rifaximina en el tratamiento de la encefalopatía hepática

Sánchez‐Delgado, J., & Miquel, M. (2015) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2015.08.003 · Cited by 9 · see citing works

Cytokines in Hepatic Injury

Fukui, H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804274-8.00027-8 · Cited by 9 · see citing works

Pioglitazone Ameliorates Acute Endotoxemia-Induced Acute on Chronic Renal Dysfunction in Cirrhotic Ascitic Rats

Liu, S.-Y., Huang, C., Huang, S., Liao, T., Kuo, N.-R., Yang, Y., Li, T., Liu, C., Hou, M., & Lin, H. (2021) · Cells · doi:10.3390/cells10113044 · Cited by 9 · see citing works

Epidemiología de las infecciones bacterianas en pacientes con cirrosis hepática. Expericencia de un centro terciario español

Klimova, K., Padilla, C., Morales, J. C. Á., Clemente, G., & Ochoa, A. (2015) · Biomédica · doi:10.7705/biomedica.v36i1.2600 · Cited by 7 · see citing works

Role of rifaximin in the treatment of hepatic encephalopathy

Sánchez‐Delgado, J., & Miquel, M. (2016) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2016.03.006 · Cited by 7 · see citing works

Evaluation of a protocol for rifaximin discontinuation in critically ill patients with liver disease receiving broad-spectrum antibiotic therapy

Ward, J. A., Yerke, J. R., Lumpkin, M., Kapoor, A., Lindenmeyer, C. C., & Bass, S. N. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i11.1226 · Cited by 6 · see citing works

Eficacia de la rifaximina en los diferentes escenarios clínicos de la encefalopatía hepática

Coronel-Castillo, C. E., Contreras-Carmona, J., Frati-Munari, A. C., Uribe, M., & Méndez‐Sánchez, N. (2019) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2019.09.001 · Cited by 6 · see citing works

Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation

Kitsugi, K., Kawata, K., Noritake, H., Chida, T., Ohta, K., Ito, J., Takatori, S., Yamashita, M., Hanaoka, T., Umemura, M., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062210 · Cited by 5 · see citing works

Current treatment options for alcohol-related liver disease

Hazeldine, S., & Sheron, N. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000065 · Cited by 5 · see citing works

Current and investigational drugs in early clinical development for portal hypertension

Sakiani, S., Heller, T., & Koh, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.974182 · Cited by 5 · see citing works

Presence of NOD2 mutations is not associated with hepatic or systemic hemodynamic abnormalities of cirrhosis

Greinert, R., Zipprich, A., Casper, M., Reichert, M., Lammert, F., & Ripoll, C. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.05.016 · Cited by 4 · see citing works

Rifaximin treatment in patients with severe alcohol-associated hepatitis: A multicenter, randomized controlled, open-label, pilot trial

Song, D. S., Yang, J. M., Jung, Y. K., Yim, H. J., Kim, H. Y., Kim, C. W., Kim, S. S., Cheong, J. Y., Lee, H. L., Lee, S. W., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101749 · Cited by 3 · see citing works

Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double‐blind, placebo‐controlled trial

Kimer, N., Pedersen, J. S., Busk, T. M., Gluud, L. L., Hobolth, L., Krag, A. A., Møller, S., Bendtsen, F., & Copenhagen Rifaximin (CoRif) Study Group (2016) · Hepatology · doi:10.1002/hep.28898 · Cited by 75 · see citing works

Intestinal decontamination improves liver haemodynamics in patients with alcohol‐related decompensated cirrhosis

VLACHOGIANNAKOS, J., SAVERIADIS, A. S., VIAZIS, N., THEODOROPOULOS, I., FOUDOULIS, K., MANOLAKOPOULOS, S., RAPTIS, S., & KARAMANOLIS, D. G. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.03958.x · Cited by 163 · see citing works

Long-term Administration of Rifaximin Improves the Prognosis of Patients With Alcoholic Liver Disease: A Case-Control Study

Richa, S., Vijay, S., & Chaturvedi, M. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.04.129

Rifaximin Reduces Endotoxemia and Improves Liver Function and Disease Severity in Patients With Decompensated Cirrhosis

Kalambokis, G. N., & Tsianos, E. V. (2011) · Hepatology · doi:10.1002/hep.24751 · Cited by 61 · see citing works

Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis

Dong, T. S., Aronsohn, A. I., Reddy, K. G., & Te, H. S. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4313-0 · Cited by 63 · see citing works